{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:27:54Z","timestamp":1778138874903,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006678","name":"Association Fran\u00e7aise pour l'Etude du Foie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clinre.2022.102059","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T11:52:31Z","timestamp":1669636351000},"page":"102059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey"],"prefix":"10.1016","volume":"47","author":[{"given":"Manon","family":"Allaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Lerosey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ganne-Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinre.2022.102059_bib0001","doi-asserted-by":"crossref","first-page":"1734\u201143","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses\u2026","volume":"41","author":"Allaire","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.clinre.2022.102059_bib0002","doi-asserted-by":"crossref","first-page":"526\u201136","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2022.102059_bib0003","doi-asserted-by":"crossref","first-page":"86\u201194","DOI":"10.1016\/j.dld.2018.07.014","article-title":"Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis","volume":"51","author":"Allaire","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.clinre.2022.102059_bib0004","doi-asserted-by":"crossref","first-page":"41\u201153","DOI":"10.1002\/ueg2.12188","article-title":"Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"10","author":"M\u00fcller","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"10.1016\/j.clinre.2022.102059_bib0005","doi-asserted-by":"crossref","first-page":"2079\u201188","DOI":"10.1002\/hep.26629","article-title":"Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study","volume":"58","author":"Ripoll","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0006","doi-asserted-by":"crossref","first-page":"500\u20118","DOI":"10.5009\/gnl19155","article-title":"Treatment Outcomes and Prognostic Factors of Acute Variceal Bleeding in Patients with Hepatocellular Carcinoma","volume":"14","author":"Lee","year":"2020","journal-title":"Gut Liver"},{"issue":"20","key":"10.1016\/j.clinre.2022.102059_bib0007","doi-asserted-by":"crossref","first-page":"1894\u2011905","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinre.2022.102059_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101785","article-title":"Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: a \u00ab menage \u00e0 trois \u00bb\u00a0!","volume":"46","author":"Campion","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0009","doi-asserted-by":"crossref","first-page":"959\u201174","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2022.102059_bib0010","doi-asserted-by":"crossref","first-page":"743\u201152","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0011","doi-asserted-by":"crossref","first-page":"378\u201190","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0012","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"69","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2022.102059_bib0013","doi-asserted-by":"crossref","first-page":"3354\u201162","DOI":"10.1007\/s10620-016-4255-6","article-title":"Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma","volume":"61","author":"Kim","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.clinre.2022.102059_bib0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12885-020-07708-1","article-title":"Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study","volume":"21","author":"Lim","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2022.102059_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15458","article-title":"A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC","author":"Larrey","year":"2022","journal-title":"Liver Int"},{"issue":"18","key":"10.1016\/j.clinre.2022.102059_bib0017","doi-asserted-by":"crossref","first-page":"2992\u20118","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2022.102059_bib0018","doi-asserted-by":"crossref","first-page":"1063\u201172","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clinre.2022.102059_bib0019","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers11071022","article-title":"Platelets as Key Factors in Hepatocellular Carcinoma","volume":"11","author":"Pavlovic","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clinre.2022.102059_bib0020","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers11101568","article-title":"Platelets and Hepatocellular Cancer: bridging the Bench to the Clinics","volume":"11","author":"Lai","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clinre.2022.102059_bib0021","doi-asserted-by":"crossref","first-page":"923\u20118","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2022.102059_bib0022","doi-asserted-by":"crossref","first-page":"481\u201192","DOI":"10.1111\/apt.16490","article-title":"Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States","volume":"54","author":"Wijarnpreecha","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinre.2022.102059_bib0023","doi-asserted-by":"crossref","first-page":"597\u2011605","DOI":"10.1080\/00365521.2020.1762919","article-title":"Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients","volume":"55","author":"Udumyan","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2022.102059_bib0024","doi-asserted-by":"crossref","first-page":"79\u201183","DOI":"10.1016\/j.dld.2019.06.019","article-title":"Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis","volume":"52","author":"Due\u00f1as","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinre.2022.102059_bib0025","unstructured":"Abou-Alfa Ghassan K., Lau G., Kudo M., Chan S.L., Kelley R.K., Furuse J., et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. 0(0):EVIDoa2100070."}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:24Z","timestamp":1761896004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2210740122001929"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102059","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102059"}}